Emory University Hospital Midtown is a 511-bed acute care teaching hospital located in the SoNo district of Atlanta, Georgia, United States, and affiliated with Emory Healthcare. The hospital's CEO is Dan Owens.

During the past decade, Emory University Hospital Midtown conducted 228 clinical trials. In the 10-year time frame, 228 clinical trials started and 118 clinical trials were completed, i.e. on average, 51.8% percent of trials that started reached the finish line to date. In the past 5 years, 87 clinical trials started and 68 clinical trials were completed. i.e. 78.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Emory University Hospital Midtown" #1 sponsor was "Emory University" with 117 trials, followed by "National Cancer Institute (NCI)" with 70 trials sponsored, "NRG Oncology" with 23 trials sponsored, "SWOG Cancer Research Network" with 17 trials sponsored and "Alliance for Clinical Trials in Oncology" with 17 trials sponsored. Other sponsors include 105 different institutions and companies that sponsored additional 64 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Emory University Hospital Midtown" #1 collaborator was "National Cancer Institute (NCI)" with 103 trials as a collaborator, "NRG Oncology" with 35 trials as a collaborator, "Canadian Cancer Trials Group" with 11 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 8 trials as a collaborator and "Sanofi" with 7 trials as a collaborator. Other collaborators include 135 different institutions and companies that were collaborators in the rest 99 trials.

According to Clinical.Site data, the most researched conditions in "Emory University Hospital Midtown" are "Coronary Artery Disease" (18 trials), "Breast Cancer" (12 trials), "Recurrent Squamous Cell Lung Carcinoma" (9 trials), "Atrial Fibrillation" (8 trials) and "Heart Failure" (8 trials). Many other conditions were trialed in "Emory University Hospital Midtown" in a lesser frequency.

Most popular intervention types in "Emory University Hospital Midtown" are "Drug" (207 trials), "Other" (104 trials), "Radiation" (87 trials), "Procedure" (75 trials) and "Biological" (72 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (41 trials), "Quality-of-Life Assessment" (36 trials), "Cisplatin" (33 trials), "Computed Tomography" (32 trials) and "Biospecimen Collection" (27 trials). Other intervention names were less common.

The vast majority of trials in "Emory University Hospital Midtown" are 300 trials for "All" genders, 38 trials for "Female" genders and 15 trials for "Male" genders.

Currently, there are NaN active trials in "Emory University Hospital Midtown". 3 are not yet recruiting, 79 are recruiting, 96 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 118 completed trials in Emory University Hospital Midtown, 6 suspended trials, and 39 terminated clinical trials to date.

Out of the total trials that were conducted in Emory University Hospital Midtown, 38 "Phase 1" clinical trials were conducted, 129 "Phase 2" clinical trials and 109 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 16 trials, and there were also 65 trials that are defined as “Not Applicable".